JMPWA
URGN icon

JP Morgan Private Wealth Advisors’s UroGen Pharma URGN Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,543
Closed -$537K – 1463
2019
Q1 		$537K Buy
14,543
+293
+2% +$12.3K ﹤0.01% 1006
2018
Q4 		$614K Sell
14,250
-2,000
-12% -$89.9K ﹤0.01% 894
2018
Q3 		$767K Buy
16,250
+4,000
+33% +$186K ﹤0.01% 919
2018
Q2 		$610K Hold
12,250
– – ﹤0.01% 942
2018
Q1 		$609K Hold
12,250
– – ﹤0.01% 802
2017
Q4 		$456K Hold
12,250
– – ﹤0.01% 900
2017
Q3 		$386K Hold
12,250
– – ﹤0.01% 946
2017
Q2 		$221K Buy
+12,250
New +$213K ﹤0.01% 1118

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

JP Morgan Private Wealth Advisors's URGN Position: Q2 2019 in Review

JP Morgan Private Wealth Advisors sold out of UroGen Pharma (URGN) in Q2 2019, closing a stake of 14,543 shares — an estimated $537K sold.

JP Morgan Private Wealth Advisors first reported a position in URGN in Q2 2017 and held it in 8 quarters. The position peaked at $767K in Q3 2018. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2019.

  • JP Morgan Private Wealth Advisors reported no remaining UroGen Pharma position as of Q2 2019 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 14,543 UroGen Pharma shares in Q2 2019, an estimated $537K.
  • JP Morgan Private Wealth Advisors first reported a position in UroGen Pharma in Q2 2017 and held it in 8 quarters.
  • JP Morgan Private Wealth Advisors's UroGen Pharma position peaked at $767K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2019.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2019, filed 7 Aug 2019.